HAVCR1 and type 2 diabetes nephropathy: In type 2 diabetic nephropathy, a high dose of benfotiamine (900 mg/day) treatment did not reduce the urinary albumin excretion (UAE) and the tubular damage marker kidney injury molecule-1 (KIM-1) after 12 weeks [77]; this study may have been too short to see the effect of benfotiamine.